Neuropathic pain remains poorly treated for large numbers of patients, and little progress
has been made in developing novel classes of analgesics. To redress this issue, ziconotide …

Chronic pain affects approximately 20% of people worldwide and places a large economic
and social burden on society. Despite the availability of a range of analgesics, this condition …

Voltage-gated calcium channels are required for many key functions in the body. In this
review, the different subtypes of voltage-gated calcium channels are described and their …

It is well recognized that voltage‐gated calcium (Ca2+) channels modulate the function of
peripheral and central pain pathways by influencing fast synaptic transmission and neuronal …

Pain represents a complex heterogeneous sensory experience, almost uniquely influenced
by emotional condition and experience. This broad description alludes to the fact that pain is …

Ziconotide (PRIALT®) is a neuroactive peptide in the final stages of clinical development as
a novel non-opioid treatment for severe chronic pain. It is the synthetic equivalent of ω …

The voltage-dependent N-type calcium channel (Cav2. 2), which is distributed in the nerve
endings of the central and peripheral nerves, is known to be strongly associated with the …

Voltage-gated calcium channel (Cav) 2.2 (N-type calcium channels) are key components in
nociceptive transmission pathways. Ziconotide, a state-independent peptide inhibitor of …

Worldwide a large number of patients suffer from severe chronic pain even after treatment
with opioids following the 3-step analgesic ladder developed by the WHO. Intraspinal …

Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiological
functions. Pathological conditions leading to changes in their biophysical properties and …